HealthMore in Health→
Pharma Industry Reshapes Licensing Deals to Blunt MFN Drug Pricing
Biopharma companies are restructuring international licensing agreements to reduce their exposure to Most Favored Nation pricing rules, which link US drug prices to the lowest prices paid in other countries.
Key Takeaways
- Pharma companies are restructuring international licensing agreements to reduce price transparency that MFN calculations would use
- Lawyers confirm the strategies are legal adaptations to evolving MFN rules, not evasion schemes
DE
DT Editorial Team··3 min read·via endpoints.news
